Abbott ABT Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Diagnostic Products | $2.18B+6.1% | $2.46B-2.5% | $2.25B-6.6% | $2.17B-1.0% | $2.05B-7.2% | |
| Established Pharmaceuticals | $1.43B+13.2% | $1.38B+9.0% | $1.51B+7.5% | $1.38B+6.9% | $1.26B+2.8% | |
| Medical Devices | $5.54B+13.2% | $5.68B+12.3% | $5.45B+14.8% | $5.37B+13.4% | $4.9B+9.9% | |
| Nutritional Products | $2.02B-6.0% | $1.94B-8.9% | $2.15B+4.2% | $2.21B+2.9% | $2.15B+3.8% | |
| Total Assets by Business | ||||||
| Diagnostic Products | $9.63B+22.8% | $8.27B+7.7% | $8.2B— | $8.18B— | $7.84B— | |
| Established Pharmaceuticals | $3.67B+6.3% | $3.54B+14.7% | $3.73B— | $3.73B— | $3.45B— | |
| Medical Devices | $10.98B+9.5% | $10.69B+12.8% | $10.58B— | $10.56B— | $10.03B— | |
| Nutritional Products | $4.9B+5.8% | $4.79B+8.8% | $4.89B— | $4.91B— | $4.64B— | |
| Operating Earnings by Business | ||||||
| Diagnostic Products | $335M-6.7% | $609M-0.3% | $400M-28.3% | $372M-13.5% | $359M-24.3% | |
| Established Pharmaceuticals | $365M+22.5% | $255M-5.9% | $391M+2.9% | $346M+9.8% | $298M+11.6% | |
| Medical Devices | $1.89B+17.7% | $1.98B+11.6% | $1.83B+20.9% | $1.8B+19.2% | $1.61B+18.3% | |
| Nutritional Products | $311M-21.1% | $386M-12.9% | $360M+15.4% | $418M+12.1% | $394M+4.5% | |
| Selling, general, and administrative by Business | ||||||
| Diagnostic Products | $448M+14.3% | $383M-6.8% | $413M+1.0% | $423M+5.8% | $392M-1.3% | |
| Established Pharmaceuticals | $376M+7.1% | $377M+15.3% | $364M+8.3% | $363M+5.5% | $351M+5.1% | |
| Medical Devices | $1.39B+7.8% | $1.39B+10.2% | $1.39B+13.8% | $1.39B+13.4% | $1.29B+9.3% | |
| Nutritional Products | $563M-2.3% | $435M-11.2% | $515M-6.4% | $585M+1.6% | $576M+4.5% | |
| Cost of products sold, excluding amortization of intangible assets by Business | ||||||
| Diagnostic Products | $1.24B+7.8% | -$8.65B+0.2% | $1.29B+0.8% | $1.22B+1.7% | $1.15B-3.0% | |
| Established Pharmaceuticals | $644M+13.2% | -$4.53B-6.2% | $714M+10.9% | $631M+6.8% | $569M-2.6% | |
| Medical Devices | $1.81B+13.5% | -$12.1B-8.1% | $1.77B+10.1% | $1.76B+8.1% | $1.6B+3.3% | |
| Nutritional Products | $1.09B-3.1% | -$8.07B-1.9% | $1.22B+6.3% | $1.16B+0.6% | $1.12B+3.3% | |
| R&D by Business | ||||||
| Diagnostic Products | $155M+2.6% | $147M-15.5% | $150M-9.1% | $154M-4.9% | $151M-2.6% | |
| Established Pharmaceuticals | $41M-2.4% | $49M+8.9% | $42M-8.7% | $43M-2.3% | $42M+2.4% | |
| Medical Devices | $444M+10.7% | $460M+17.6% | $462M+13.2% | $430M+13.5% | $401M+9.0% | |
| Nutritional Products | $54M+3.8% | $52M+2.0% | $55M+3.8% | $54M+1.9% | $52M0.0% | |
| Additions to Property and Equipment by Business | ||||||
| Diagnostic Products | $128M-5.2% | $292M+3.2% | $168M-8.2% | $166M-1.8% | $135M+9.8% | |
| Established Pharmaceuticals | $20M-39.4% | $59M-9.2% | $38M-26.9% | $39M+5.4% | $33M+13.8% | |
| Medical Devices | $147M-5.8% | $217M+16.7% | $140M-7.3% | $145M-8.2% | $156M+15.6% | |
| Nutritional Products | $40M-49.4% | $71M-29.0% | $71M-33.0% | $81M-21.4% | $79M+8.2% | |
| Remaining performance obligations by Business | ||||||
| Diagnostic Products | $6.2B+8.8% | $6.1B+10.9% | $6B+13.2% | $5.9B+22.9% | $5.7B+26.7% | |
| Medical Devices | $429M+1.4% | $444M+0.9% | $436M-6.4% | $427M-13.4% | $423M-14.5% | |
| Depreciation by Business | ||||||
| Diagnostic Products | $144M+14.3% | $136M+1.5% | $136M+5.4% | $135M+4.7% | $126M-2.3% | |
| Established Pharmaceuticals | $30M+30.4% | $25M0.0% | $28M+21.7% | $25M+4.2% | $23M-4.2% | |
| Medical Devices | $100M+13.6% | $99M+20.7% | $97M+11.5% | $94M+8.0% | $88M+1.1% | |
| Nutritional Products | $50M+19.0% | $42M-2.3% | $47M+23.7% | $44M+12.8% | $42M+7.7% | |
| Goodwill, non-deductible by Business | ||||||
| Diagnostic Products | $14.9B+326% | $3.6B+2.9% | $3.6B0.0% | $3.6B+2.9% | $3.5B0.0% | |
| Established Pharmaceuticals | $2.7B+3.8% | $2.7B+3.8% | $2.7B0.0% | $2.7B+3.8% | $2.6B-3.7% | |
| Medical Devices | $17.3B+2.4% | $17.4B+3.6% | $17.4B+1.8% | $17.3B+2.4% | $16.9B0.0% | |
| Nutritional Products | $300M+5.3% | $285M0.0% | $285M0.0% | $285M0.0% | $285M0.0% | |
| Net Sales by Geography | ||||||
| International | $6.89B+11.3% | $7.08B+6.7% | $7.07B+9.9% | $6.87B+6.6% | $6.19B+1.2% | |
| United States | $4.27B+2.5% | $4.38B+1.0% | $4.3B+2.3% | $4.28B+8.7% | $4.17B+8.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Abbott break its business down?
- Abbott (ABT) reports net sales by business across 4 parts — Diagnostic Products, Established Pharmaceuticals, Medical Devices and Nutritional Products. Each is extracted from the segment footnotes and tracked over time.
- Where does Abbott's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Abbott's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
